WO2016199851A1 - 血清または血漿分離用組成物、血液検査用容器、並びに血清または血漿分離用組成物の安定化方法 - Google Patents
血清または血漿分離用組成物、血液検査用容器、並びに血清または血漿分離用組成物の安定化方法 Download PDFInfo
- Publication number
- WO2016199851A1 WO2016199851A1 PCT/JP2016/067210 JP2016067210W WO2016199851A1 WO 2016199851 A1 WO2016199851 A1 WO 2016199851A1 JP 2016067210 W JP2016067210 W JP 2016067210W WO 2016199851 A1 WO2016199851 A1 WO 2016199851A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- serum
- plasma
- thermoplastic elastomer
- composition
- plasma separation
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5002—Partitioning blood components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
- B01L3/50215—Test tubes specially adapted for centrifugation purposes using a float to separate phases
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L45/00—Compositions of homopolymers or copolymers of compounds having no unsaturated aliphatic radicals in side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic or in a heterocyclic ring system; Compositions of derivatives of such polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L57/00—Compositions of unspecified polymers obtained by reactions only involving carbon-to-carbon unsaturated bonds
- C08L57/02—Copolymers of mineral oil hydrocarbons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5082—Test tubes per se
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/03—Polymer mixtures characterised by other features containing three or more polymers in a blend
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2207/00—Properties characterising the ingredient of the composition
- C08L2207/04—Thermoplastic elastomer
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L65/00—Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain; Compositions of derivatives of such polymers
Definitions
- the present invention is used to separate serum or plasma from blood, more specifically, a serum or plasma separation composition for separating serum or plasma from blood by utilizing the specific gravity difference of blood components,
- the present invention relates to a blood test container containing the serum or plasma separating composition and a method for stabilizing the serum or plasma separating composition.
- a thixotropic composition is widely used from the viewpoint of stability during transportation and storage, and from the viewpoint of maintaining a stable separation state even after centrifugation. ing.
- a composition having thixotropy blood separation can be easily performed by centrifugation regardless of the technical difference of the user.
- Patent Document 1 discloses a serum or plasma separation composition in which an inorganic powder is dispersed in a liquid organic compound component for the purpose of adjusting specific gravity and imparting thixotropy.
- Patent Documents 1 and 2 disclose compositions for separating serum or plasma in which various organic compounds such as polyoxyethylene polyoxypropylene block copolymers and silicone surfactants are blended as thixotropic enhancers. It is disclosed.
- the thixotropy-imparting agent and thixotropic enhancer disclosed in Patent Documents 1 and 2 are intended to obtain thixotropy by forming a hydrogen bonding network in a liquid organic compound.
- An object of the present invention is to provide a serum or plasma separation composition in which a liquid organic compound and a thixotropy-imparting component are difficult to separate and a uniform blended state can be maintained over a long period of time, and the serum or plasma separation composition
- An object of the present invention is to provide a container for blood test and a method for stabilizing a serum or plasma separation composition.
- the inventors of the present application have found that the composition containing the liquid organic compound and the thixotropy-imparting component is further mixed with a thermoplastic elastomer, so that these components are difficult to separate from each other and are uniform.
- the inventors have found that a composition for separating serum or plasma capable of maintaining the blended state for a long period of time can be obtained, and the present invention has been completed.
- the serum or plasma separation composition according to the present invention includes a liquid organic compound, a thixotropic component, and a thermoplastic elastomer.
- the liquid organic compound includes a liquid resin.
- the thermoplastic elastomer is a styrene thermoplastic elastomer, a urethane thermoplastic elastomer, an ester thermoplastic elastomer, an amide thermoplastic elastomer, an acrylic It is at least one selected from the group consisting of thermoplastic thermoplastic elastomers and olefinic thermoplastic elastomers.
- thermoplastic elastomer is a styrenic thermoplastic elastomer.
- the content of the thermoplastic elastomer is 0.5 to 50% by weight.
- the liquid organic compound is a mixture of at least one of a petroleum resin and a dicyclopentadiene resin and a benzenepolycarboxylic acid alkyl ester. It is characterized by that.
- the thixotropic property-imparting component contains an inorganic fine powder.
- the inorganic fine powder is at least one of hydrophilic silica and hydrophobic silica.
- composition for separating serum or plasma further contains an organic gelling agent.
- the blood test container according to the present invention is characterized in that it contains therein a serum or plasma separation composition constituted according to the present invention.
- the method for stabilizing a serum or plasma separation composition according to the present invention is characterized in that a thermoplastic elastomer is further contained in the serum or plasma separation composition containing a liquid organic compound and a thixotropic component.
- the thermoplastic elastomer in addition to the liquid organic compound and the thixotropy-imparting component, the thermoplastic elastomer is blended, so that the composition is exposed to a high temperature of 50 to 60 ° C. Even in this case, the liquid organic compound and the thixotropic property-imparting component are difficult to separate, and the uniformity as a blend can be maintained over a long period.
- the blood test container according to the present invention contains the serum or plasma separation composition provided by the above aspect, the serum or plasma separation composition is stored during storage or transportation of the blood test container. The flow due to the phase separation of things is difficult to occur.
- the composition for separating serum or plasma according to the present invention includes a liquid organic compound, a thixotropic component, and a thermoplastic elastomer. Therefore, in the serum or plasma separation composition of the present invention, the liquid organic compound and the thixotropy-imparting component are difficult to separate, and a uniform blended state can be maintained over a long period of time.
- the serum or plasma separation composition of the present invention contains a liquid organic compound.
- the liquid organic compound in the serum or plasma separation composition of the present invention includes a resin that takes a liquid state at ⁇ 10 ° C. or higher in consideration of the temperature range in which the blood sample is frozen, and has a partition wall-forming property. It is not particularly limited as long as it has fluidity necessary for expression and satisfies the required specific gravity.
- the state satisfying the specific gravity means that the density ratio of the liquid organic compound at 25 ° C. to the density of water at 4 ° C. is 0.9 to 1.1.
- Such a liquid organic compound is preferably a liquid resin.
- the liquid resin that can be used in the present invention is not particularly limited.
- known liquid resins such as copolymer resins of 1,3-propanediol and 1,2-propanediol, polyether polyurethane resins, or polyether polyester resins.
- liquid organic compounds liquid mixtures of poly- ⁇ -pinene polymers and chlorinated hydrocarbons, liquid mixtures of chlorinated polybutenes and epoxidized animal and vegetable oils, ethylene trifluoride chloride, benzene polycarboxylic acid alkyl ester derivatives, etc.
- C 5 fraction including cyclopentadiene, isoprene, piperylene, 2-methylbutene-1,2-methylbutene -2, etc.
- C 9 fraction including styrene, vinyl toluene, ⁇ -methyl styrene, indene, coumarone, etc. alone or copolymer, copolymer of C 5 fraction and C 9 fraction, etc.
- Petroleum resin or dicyclopentadiene resin composed of non-hydrogenated, partially hydrogenated or completely hydrogenated product Such emission Zen polycarboxylic acid alkyl ester derivatives such as a mixture of liquid at the liquid / liquid or solid / consist of a combination of liquid -10 ° C. or more can also be used. Said liquid organic compound may be used independently according to the performance requested
- Examples of the benzene polycarboxylic acid alkyl ester derivatives include phthalic acid esters, trimellitic acid esters, and pyromellitic acid esters.
- a solid / liquid liquid mixture or a liquid mixture such as a solid / liquid resin may be mixed separately in the production process of the serum or plasma separation composition.
- the liquid organic compound is preferably a mixture of at least one of a petroleum resin and a dicyclopentadiene resin and a benzene polycarboxylic acid alkyl ester. In that case, the liquid organic compound and the thixotropic property-imparting component are more difficult to separate, and the uniformity as a blend can be maintained for a longer period of time.
- composition for separating serum or plasma of the present invention contains a thixotropic component.
- the thixotropy-imparting component used in the present invention is not particularly limited as long as it is a substance that can be dispersed in a liquid organic compound to impart thixotropy.
- the inorganic thixotropic property-imparting component include inorganic fine powders produced by a known gas phase method (also referred to as dry method) or precipitation method. Examples thereof include silicon dioxide-based or silicate-based hydrophilic or hydrophobic inorganic fine powders such as clay minerals composed of silica, kaolinite, smectite, and the like.
- silica fine powder having a low content of alkali metal or alkaline earth metal element.
- silica fine powders those that are hydrophilic include Aerosil series such as Aerosil 130, 200, 300 (manufactured by Nippon Aerosil Co., Ltd.), Leorosil series such as Leorosil QS10, QS20, QS30 (Manufactured by Tokuyama Corporation), WACKER HDK.
- Gas phase method hydrophilic silica such as WACKER HDK series (manufactured by Asahi Kasei Wacker Silicone Co., Ltd.) such as S13, N20, and T30 can be mentioned.
- hydrophobic ones such as Aerosil series such as Aerosil R972, R974, R805, R812, OX50 (manufactured by Nippon Aerosil Co., Ltd.), Leolosil MT10, DM30S, HM30S, KS20S, PM20, etc.
- Gas phase method hydrophobic silica such as seal series (manufactured by Tokuyama), WACKER HDK series (manufactured by Asahi Kasei Wacker Silicone) such as WACKER HDK H15, H18, H30, etc. is easily available and easy to use.
- Hydrophilic silica and hydrophobic silica may be used alone or in combination.
- the inorganic fine powder is used not only for imparting thixotropy but also as a specific gravity adjuster.
- examples of the organic thixotropic property-imparting component used in the present invention include organic gelling agents such as dibenzylidene sorbitol and its derivatives and fatty acid amides.
- dibenzylidene sorbitol and its derivatives examples include gelall series (manufactured by Shin Nippon Chemical Co., Ltd.) such as gelol MD and gelall D.
- an organic solvent such as dimethyl sulfoxide, N, N-dimethylformamide, or 1-methyl-2-pyrrolidone may be appropriately used as an auxiliary solvent. Good.
- organic compounds having polar groups such as polyoxyethylene polyoxypropylene block copolymers and silicone surfactants may be appropriately used in combination as thixotropic enhancers.
- a small amount of purified water may be used in combination as appropriate.
- Thermoplastic elastomers contains a thermoplastic elastomer.
- thermoplastic elastomer used in the present invention is obtained by block copolymerization of a monomer constituting a hard segment and a monomer constituting a soft segment in one molecule.
- the hard segment is a crystalline segment if it is a crystalline polymer, and a hard segment having a high glass transition point (Tg) in the case of an amorphous polymer.
- the soft segment refers to a segment with low Tg and high flexibility.
- the molecular weight, the number of blocks, etc. are not particularly limited.
- any of triblocks composed of (hard / soft / hard) segments, diblocks composed of (hard / soft) segments, etc. may be used. It may be. Moreover, it may have a linear structure or a branched structure, or a mixture thereof. Further, double bonds contained in the molecule may be hydrogenated to various degrees.
- thermoplastic elastomers such as styrene-based and olefin-based ones
- polar groups containing hetero elements may be introduced.
- Thermoplastic elastomers do not have chemical crosslinking points, so they are soluble in organic solvents and exhibit plasticity at high temperatures. However, at normal temperature, the hard segment is crystallized to become a physical cross-linking point, and thus exhibits properties as an elastomer.
- various known thermoplastic elastomers such as styrene-based, urethane-based, ester-based, amide-based, acrylic-based, and olefin-based materials can be used, but the soft segment is rich in compatibility with the liquid organic compound. In order to retain the liquid organic compound in the serum or plasma separation composition, it is desirable to select a combination of the hard segment that is poorly compatible with the liquid organic compound.
- the molecular weight is not particularly limited, but if it is too low, the properties as an elastomer may be poor, and if it is too high, it may be difficult to dissolve in a liquid organic compound. At this time, in order to give a better partition wall forming performance, it can be added more easily with a liquid organic compound and when the serum or plasma separation composition is used, preferably in a weight average molecular weight, preferably 10,000 or more, 500,000. Or less, more preferably 10,000 or more and 300,000 or less.
- constituent elements of the hard segment include polystyrene, polyester such as polyurethane and polybutylene terephthalate, polyamide, and the like.
- examples of the constituent elements of the soft segment include polydienes, polydienes hydrogenated to various degrees, polyethers, polyesters, and polycarbonates.
- a polystyrene segment acts as a hard segment, and polydienes or polydienes hydrogenated to various degrees act as soft segments.
- thermoplastic elastomers examples include styrene-butadiene-styrene copolymer (SBS), styrene-isoprene-styrene copolymer (SIS), and styrene-ethylene-butylene-styrene copolymer (SEBS).
- SBS styrene-butadiene-styrene copolymer
- SIS styrene-isoprene-styrene copolymer
- SEBS styrene-ethylene-butylene-styrene copolymer
- Styrene-butadiene-butylene-styrene copolymer SBBS
- triblock copolymers such as styrene-ethylene-propylene-styrene copolymer (SEPS), and modified products thereof
- SEPS styrene-ethylene-propylene-styrene copolymer
- SB styrene-butadiene copolymer Diblocks such as styrene-isoprene copolymer (SI), styrene-ethylene-butylene copolymer (SEB), styrene-butadiene-butylene copolymer (SBB), and styrene-ethylene-propylene copolymer (SEP) Examples thereof include copolymers and modified products thereof.
- styrenic thermoplastic elastomer examples include Tuftec P1500, P1083, P5051 (styrene / butadiene / butylene / styrene), H1041, H1052, H1221 (styrene / ethylene / butylene / styrene), M1911, M1913 (modified elastomer), and the like.
- Elastollan 1180A, S80A, C80A, ET680, ET880 ether / isocyanate, ester / isocyanate), etc. (manufactured by BASF) are easily available.
- Hytrel 3046 As the ester-based thermoplastic elastomer, Hytrel 3046, SB654 (butylene terephthalate / ether), etc. (manufactured by Toray DuPont) are easily available.
- amide-based thermoplastic elastomer Pebax 2533, 3533 (amide / ether) and the like (manufactured by Arkema) are easily available.
- clarity LA1114, LA2140e, LA2250 (methyl methacrylate / butyl acrylate) or the like is easily available.
- Dynalon 6100P, 6200P crystalline olefin / ethylene / butylene
- JSR manufactured by JSR
- thermoplastic elastomers are most flexible, and are therefore excellent in compatibility with liquid resin components and easily maintain fluidity as a composition for separating serum or plasma.
- thermoplastic elastomer and the partition wall-forming liquid organic compound may be mixed by heating. If necessary, an organic solvent such as toluene, N, N-dimethylformamide, or 1-methyl-2-pyrrolidone may be used. May be used as an auxiliary solvent.
- an organic solvent such as toluene, N, N-dimethylformamide, or 1-methyl-2-pyrrolidone may be used. May be used as an auxiliary solvent.
- the blending ratio of the thermoplastic elastomer is preferably 0.5 to 50% by weight, more preferably 1 to 20% by weight, and still more preferably 1 to 10% by weight.
- the blending concentration is too low, the effect of maintaining the blending uniformity as a serum or plasma separation composition is poor, and if the blending concentration is too high, it becomes difficult to dissolve in a liquid organic compound, and the composition has a viscous property. This is not preferable because it becomes too high and requires a large centrifugal force to form the partition wall.
- the serum or plasma separation composition of the present invention contains a liquid organic compound, a thixotropic component, and a thermoplastic elastomer. Therefore, the liquid organic compound and the thixotropic property-imparting component are difficult to separate, and a uniform blended state can be maintained over a long period of time.
- the method for producing the serum or plasma separation composition provided by the present invention is not particularly limited.
- the liquid organic compound and the thermoplastic elastomer may be heated and dissolved, and then inorganic powder as a thixotropic property-imparting component may be blended and mixed.
- the mixing method is not particularly limited, and a known kneading method such as a planetary mixer, a roll mill, or a homogenizer may be used.
- the blood test container of the present invention contains a serum or plasma separation composition therein.
- the shape of the blood test container is not particularly limited, and a known bottomed tubular container having an opening at one end may be used.
- the material for the blood test container is not particularly limited, and a known glass or thermoplastic resin such as polyethylene, polypropylene, polystyrene, polyacrylate, polymethacrylate, or polyethylene terephthalate may be used.
- a known glass or thermoplastic resin such as polyethylene, polypropylene, polystyrene, polyacrylate, polymethacrylate, or polyethylene terephthalate may be used.
- the serum or plasma separation composition When separating serum or plasma from blood using the serum or plasma separation composition according to the present invention, for example, the serum or plasma separation composition is accommodated in the bottom or side wall of the blood test container, and thereafter Then, blood as a sample is collected in a container.
- the serum or plasma separation composition is located in these intermediate layers to form a partition that separates them.
- the inside of the blood test container may be decompressed according to the blood sampling method. Moreover, the inside may be sterilized according to the requirements of existing standards such as JIS and ISO.
- the blood test container of the present invention can accommodate a known drug in the interior depending on the purpose of the test.
- the medicine can take a known form, such as being applied to the inner wall in advance, or being granulated and accommodated inside the container.
- an anticoagulant such as heparin or ethylenediaminetetraacetic acid (EDTA) may be contained inside the blood test container.
- EDTA ethylenediaminetetraacetic acid
- serum separation in order to shorten the blood coagulation time, silica, diatomaceous earth, kaolinite, fine powders such as silicate, silicates, etc., or enzymes such as thrombin, snake venom, etc. May be housed in a blood test container.
- thermoplastic elastomer (Substance used as thermoplastic elastomer)
- Example 1 As a benzenepolycarboxylic acid alkyl ester derivative, trimellitic acid ester (manufactured by DIC, trade name: Monosizer W700) and a styrene-based thermoplastic elastomer (trade name: Tough Tech P1500, manufactured by Asahi Kasei Chemicals) are dissolved by heating at 160 ° C. Then, petroleum resin (trade name: Ligalite S5090, manufactured by Eastman Chemical Co., Ltd.) and dicyclopentadiene resin (trade name: Scolletz SU500, SU90, manufactured by Colon Co., Ltd.) are added and dissolved by heating at about 160 ° C. to form a liquid organic material.
- trimellitic acid ester manufactured by DIC, trade name: Monosizer W700
- a styrene-based thermoplastic elastomer trade name: Tough Tech P1500, manufactured by Asahi Kasei Chemicals
- a compound was prepared, and a 1-methyl-2-pyrrolidone (NMP, manufactured by Wako Pure Chemical Industries, Ltd.) solution of dibenzylidene sorbitol (manufactured by Shin Nippon Rika Co., Ltd., trade name: Gelol D) as an organic gelling agent was added, Cooled to 35 ° C. Next, while stirring the liquid organic compound with a planetary mixer, hydrophilic fine powder silica (produced by Nippon Aerosil Co., Ltd., trade name: Aerosil 200CF) and hydrophobic fine powder silica (produced by Nippon Aerosil Co., Ltd.) Trade name: Aerosil R974) was dispersed in the liquid organic compound, followed by the addition of purified water. Thus, the serum or plasma separation composition of Example 1 was obtained. In addition, the mixture ratio of each component is as showing in Table 4 below.
- Examples 2 to 8 and Comparative Example 1 A serum or plasma separation composition was obtained in the same manner as in Example 1 except that the blending ratio of each component was changed as shown in Table 4.
- phase separation resistance The 20 10 mL blood test containers prepared above were each divided into two groups, one group being allowed to stand at about 55 ° C. for one day in an obliquely downward state, and the remaining groups being in an obliquely downward state. And left at about 55 ° C. for 5 days.
- the presence or absence of oozing of the liquid component was observed from the initial liquid surface position of the serum or plasma separation composition, and the oozing length was measured for those that oozed, The average value was obtained to evaluate the phase separation resistance.
- the 20 prepared 10 mL blood test containers were allowed to stand for 5 days in an upright state at 55 ° C., and then divided into two groups. One group was allowed to stand at 35 ° C. for 1 day in an obliquely downward state. The rest of the groups were allowed to stand at about 35 ° C. for 5 days in a diagonally downward direction. For these still-heated products, the presence or absence of oozing of the liquid component was observed from the initial liquid surface position of the serum or plasma separation composition, and the oozing length was measured for those that oozed, The average value was obtained to evaluate the phase separation resistance.
- Example 9 to 21 were examined in order to confirm the effect of the invention even in a thermoplastic elastomer of a type different from that used in Examples 1 to 8.
- Table 6 shows the thermoplastic elastomers used in Examples 9-21.
- Table 7 shows the blending ratio of each component of the serum or plasma separation composition.
- Example 9 to 13 and Comparative Example 2 A serum or plasma separation composition was obtained in the same manner as in Example 1 except that different types of thermoplastic elastomers were used and the blending ratio of each component was changed as shown in Table 7. .
- Example 14 to 21 Except that different types of thermoplastic elastomers were used, that the auxiliary solvent 1-methyl-2-pyrrolidone (NMP) was not used, and the blending ratio of each component was changed as shown in Table 7. In the same manner as in Example 1, a serum or plasma separation composition was obtained.
- NMP auxiliary solvent 1-methyl-2-pyrrolidone
- the 20 prepared 10 mL blood test containers were allowed to stand in an upright state at about 55 ° C. for 5 days, and then divided into two groups. The group was allowed to stand at about 35 ° C. for 1 day in an obliquely downward state, and the remaining groups were left to stand at about 35 ° C. for 5 days in an obliquely downward state.
- the presence or absence of oozing of the liquid component was observed from the initial liquid surface position of the serum or plasma separation composition, and the oozing length was measured for those that oozed, The average value was obtained to evaluate the phase separation resistance.
- the serum or plasma separation composition containing the thermoplastic elastomers of Examples 1 to 21 resists the aggregating force caused by hydrogen bonding networks such as inorganic fine powders and organic gelling agents. It was found that the uniformity of the blended state of the components can be maintained over a long period of time.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Ecology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Clinical Laboratory Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
本発明に係る血清または血漿分離用組成物のある特定の局面では、前記液状有機化合物が、液状樹脂を含むことを特徴とする。
本発明に係る血清または血漿分離用組成物の安定化方法は、液状有機化合物とチクソトロピー性付与成分とを含む血清または血漿分離用組成物に、熱可塑性エラストマーをさらに含ませることを特徴とする。
本発明に係る血清または血漿分離用組成物は、液状有機化合物と、チクソトロピー性付与成分と、熱可塑性エラストマーとを含む。そのため、本発明の血清または血漿分離用組成物では、液状有機化合物とチクソトロピー性付与成分とが分離し難く、均一な配合状態を長期間に渡って維持することができる。
本発明の血清又は血漿分離用組成物は、液状有機化合物を含有する。
本発明の血清又は血漿分離用組成物は、チクソトロピー性付与成分を含有する。
本発明の血清または血漿分離用組成物は、熱可塑性エラストマーを含有する。
本発明により提供される血清または血漿分離用組成物の製造方法は特に限定されない。例えば、上記液状有機化合物と上記熱可塑性エラストマーとを加熱溶解させた後、チクソトロピー性付与成分としての無機粉末を配合し、混合すればよい。混合方法は、特に限定されることはなく、プラネタリーミキサー、ロールミル、ホモジナイザー等の公知の混練方法を用いればよい。
本発明の血液検査用容器は、血清または血漿分離用組成物を内部に収容してなる。この血液検査用容器の形状は、特に制限されることはなく、公知の、一端に開口部を有する有底管状容器を用いればよい。
実施例及び比較例において用いた物質は以下の通りである。
ベンゼンポリカルボン酸アルキルエステル誘導体としてトリメリット酸エステル(DIC社製、商品名:モノサイザーW700)とスチレン系熱可塑性エラストマー(旭化成ケミカルズ社製、商品名:タフテックP1500)とを160℃で加熱溶解し、次いで、石油樹脂(イーストマンケミカル社製、商品名:リガライトS5090)、ジシクロペンタジエン樹脂(コロン社製、商品名:スコレッツSU500,SU90)を加えて、約160℃で加熱溶解して液状有機化合物を調製し、有機ゲル化剤としてのジベンジリデンソルビトール(新日本理化社製、商品名:ゲルオールD)の1-メチル-2-ピロリドン(NMP,和光純薬工業社製)溶液を加えて、35℃まで冷却した。次に、プラネタリ―ミキサーで上記液状有機化合物を撹拌しつつ、無機微粉末として、親水性微粉末シリカ(日本アエロジル社製、商品名:アエロジル200CF)及び疎水性微粉末シリカ(日本アエロジル社製、商品名:アエロジルR974)を、上記液状有機化合物中に分散させ、続いて精製水を添加した。このようにして、実施例1の血清または血漿分離用組成物を得た。なお、各成分の配合割合は、下記の表4に示すとおりである。
各成分の配合割合を表4に示したように変更したことを除いては、実施例1と同様にして、血清または血漿分離用組成物を得た。
10mL容量のポリエチレンテレフタレート製試験管(直径16mm×長さ100mm)20本に、上記血清または血漿分離用組成物を約1.2gずつ収容し、実施例1~8及び比較例1について、それぞれ20本の血液検査用容器を作製した。
1)<比重及び粘度の評価>
各血清または血漿分離用組成物の25℃における比重を浮沈法により測定した。
上記で作製した20本の10mL容量の血液検査用容器をそれぞれ2グループに分け、ひとつのグループは、斜め下向きの状態で約55℃で1日静置し、残りのグループは、斜め下向きの状態で約55℃で5日間静置した。これらの加熱静置品について、血清または血漿分離用組成物の最初の液面位置から液状成分の滲み出しの有無を観察し、滲み出しのあったものについては滲み出しの長さを測定し、平均値を求めて相分離耐性を評価した。
実施例1~8及び比較例1の評価結果を表5にまとめた。
実施例1~8で用いられたものとは異なる種類の熱可塑性エラストマーにおいても、発明の効果を確認すべく実施例9~21を検討した。
実施例9~21において使用した熱可塑性エラストマーを表6に示す。また、血清または血漿分離用組成物の各成分の配合割合を表7に示す。
異なる種類の熱可塑性エラストマーを用いたこと、各成分の配合割合を表7に示したように変更したことを除いては、実施例1と同様にして、血清または血漿分離用組成物を得た。
異なる種類の熱可塑性エラストマーを用いたこと、補助溶媒の1-メチル-2-ピロリドン(NMP)を用いなかったこと、各成分の配合割合を表7に示したように変更したことを除いては、実施例1と同様にして、血清または血漿分離用組成物を得た。
実施例9~21及び比較例2について、実施例1と同様の方法で、それぞれ20本の血液検査用容器を作製した。
1)<比重及び粘度の評価>
実施例9~21及び比較例2について、実施例1と同様に行った。
2)<相分離耐性の評価>
実施例9~21及び比較例2の評価結果を表8にまとめた。
Claims (11)
- 液状有機化合物と、チクソトロピー性付与成分と、熱可塑性エラストマーとを含む、血清または血漿分離用組成物。
- 前記液状有機化合物が、液状樹脂を含むことを特徴とする、請求項1に記載の血清または血漿分離用組成物。
- 前記熱可塑性エラストマーが、スチレン系熱可塑性エラストマー、ウレタン系熱可塑性エラストマー、エステル系熱可塑性エラストマー、アミド系熱可塑性エラストマー、アクリル系熱可塑性エラストマー及びオレフィン系熱可塑性エラストマーからなる群から選択される少なくとも1種であることを特徴とする、請求項1又は2に記載の血清または血漿分離用組成物。
- 前記熱可塑性エラストマーが、スチレン系熱可塑性エラストマーであることを特徴とする、請求項1~3のいずれか1項に記載の血清または血漿分離用組成物。
- 前記熱可塑性エラストマーの含有量が、0.5~50重量%である、請求項1~4のいずれか1項に記載の血清または血漿分離用組成物。
- 前記液状樹脂成分が、石油樹脂及びジシクロペンタジエン樹脂のうち少なくとも一方と、ベンゼンポリカルボン酸アルキルエステルとの混合物であることを特徴とする、請求項2~5のいずれか一項に記載の血清または血漿分離用組成物。
- 前記チクソトロピー性付与成分として、無機微粉末を含有することを特徴とする、請求項1~6のいずれか一項に記載の血清または血漿分離用組成物。
- 前記無機微粉末が、親水性シリカ及び疎水性シリカのうち少なくとも一方であることを特徴とする、請求項7に記載の血清または血漿分離用組成物。
- 前記血清または血漿分離用組成物が、さらに有機ゲル化剤を含有することを特徴とする、請求項1~8のいずれか一項に記載の血清または血漿分離用組成物。
- 請求項1~9のいずれか一項に記載の血清または血漿分離用組成物を内部に収容してなることを特徴とする、血液検査用容器。
- 液状有機化合物とチクソトロピー性付与成分とを含む血清または血漿分離用組成物に、熱可塑性エラストマーをさらに含ませることを特徴とする、血清または血漿分離用組成物の安定化方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017518557A JP6161184B2 (ja) | 2015-06-10 | 2016-06-09 | 血清または血漿分離用組成物、血液検査用容器、並びに血清または血漿分離用組成物の安定化方法 |
CN201680033584.XA CN107636459B (zh) | 2015-06-10 | 2016-06-09 | 血清或血浆分离用组合物、血液检查用容器、以及血清或血浆分离用组合物的稳定化方法 |
EP16807557.0A EP3309547B1 (en) | 2015-06-10 | 2016-06-09 | Serum- or plasma-separating composition, blood-test container, and method of stabilizing serum- or plasma-separating composition |
US15/576,689 US10677778B2 (en) | 2015-06-10 | 2016-06-09 | Serum- or plasma-separating composition, blood-test container, and method of stabilizing serum- or plasma-separating composition |
KR1020177024276A KR102424605B1 (ko) | 2015-06-10 | 2016-06-09 | 혈청 또는 혈장 분리용 조성물, 혈액 검사용 용기, 그리고 혈청 또는 혈장 분리용 조성물의 안정화 방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-117449 | 2015-06-10 | ||
JP2015117449 | 2015-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016199851A1 true WO2016199851A1 (ja) | 2016-12-15 |
Family
ID=57503308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/067210 WO2016199851A1 (ja) | 2015-06-10 | 2016-06-09 | 血清または血漿分離用組成物、血液検査用容器、並びに血清または血漿分離用組成物の安定化方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10677778B2 (ja) |
EP (1) | EP3309547B1 (ja) |
JP (1) | JP6161184B2 (ja) |
KR (1) | KR102424605B1 (ja) |
CN (1) | CN107636459B (ja) |
WO (1) | WO2016199851A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020235544A1 (ja) | 2019-05-20 | 2020-11-26 | 積水メディカル株式会社 | 単核球含有血漿分離用組成物及び血液採取容器 |
EP3734273A4 (en) * | 2017-12-27 | 2021-09-22 | Sekisui Medical Co., Ltd. | COMPOSITION FOR THE SEPARATION OF BLOOD SERUM OR BLOOD PLASMA, BLOOD COLLECTION CONTAINER AND METHOD FOR SEPARATION OF BLOOD SERUM OR BLOOD PLASMA |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3902914A4 (en) * | 2018-12-24 | 2022-10-12 | Deltadna Biosciences Inc | COMPOSITION AND METHOD FOR SEGREGATION OF EXTRACELLULAR DNA IN BLOOD |
CN113358621B (zh) * | 2021-06-10 | 2022-11-18 | 深圳市核子基因科技有限公司 | 一种同轴光纤荧光基因检测装置及其检测方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1010122A (ja) * | 1995-08-28 | 1998-01-16 | Sekisui Chem Co Ltd | 血清又は血漿分離用組成物 |
JP2002365282A (ja) * | 2001-06-05 | 2002-12-18 | Sekisui Chem Co Ltd | 血清または血漿分離用組成物 |
WO2011105151A1 (ja) * | 2010-02-26 | 2011-09-01 | 積水メディカル株式会社 | 血清または血漿分離用組成物及び血液検査用容器 |
JP2013061283A (ja) * | 2011-09-14 | 2013-04-04 | Sekisui Medical Co Ltd | 血清または血漿分離用組成物の滅菌方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4049692A (en) | 1974-12-16 | 1977-09-20 | Corning Glass Works | Stabilized blood separating composition |
US3986962A (en) * | 1975-07-10 | 1976-10-19 | Becton, Dickinson And Company | Novel assembly for separating blood |
US4021340A (en) * | 1975-11-28 | 1977-05-03 | Corning Glass Works | Blood separating composition |
US4235725A (en) | 1978-08-16 | 1980-11-25 | Owens-Illinois, Inc. | Sterile blood-collecting and separating device |
US4457782A (en) * | 1980-08-18 | 1984-07-03 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Composition for partitioning blood components |
JPS5911863A (ja) | 1982-07-13 | 1984-01-21 | 東レ株式会社 | 手術用縫合糸 |
US4994393A (en) * | 1989-02-22 | 1991-02-19 | Becton, Dickinson And Company | Blood partitioning composition |
JP3063799B2 (ja) * | 1991-10-16 | 2000-07-12 | 株式会社ニッショー | 血液分離剤 |
AU649828B2 (en) * | 1992-04-20 | 1994-06-02 | Sekisui Chemical Co., Ltd. | Serum and plasma separating compositions and blood testing containers |
US5529821A (en) * | 1992-06-29 | 1996-06-25 | Terumo Kabushiki Kaisha | Container for storing blood or blood component |
CN1046036C (zh) * | 1993-06-09 | 1999-10-27 | 中国科学院大连化学物理研究所 | 一种血清分离胶 |
CA2203759A1 (en) | 1995-08-28 | 1997-03-06 | Ryusuke Okamoto | Serum or plasma separating compositions |
US6793892B1 (en) | 1999-12-06 | 2004-09-21 | Volker Niermann | Device and method for separating components of a fluid sample |
JP2001165928A (ja) | 1999-12-08 | 2001-06-22 | Sekisui Chem Co Ltd | 血清または血漿分離用組成物、及びその製造方法 |
CN1125338C (zh) * | 2000-08-08 | 2003-10-22 | 湖北医科大学 | 血液分离胶 |
DE60231236D1 (de) * | 2001-12-04 | 2009-04-02 | Sekisui Chemical Co Ltd | Zusammensetzung zur trennung von blutserum oder -plasma und diese enthaltendes gefäss zur blutuntersuchung |
US20050124965A1 (en) * | 2003-12-08 | 2005-06-09 | Becton, Dickinson And Company | Phosphatase inhibitor sample collection system |
AU2009274096B2 (en) | 2008-07-21 | 2012-08-02 | Becton, Dickinson And Company | Density phase separation device |
CN102309870A (zh) | 2011-06-17 | 2012-01-11 | 上海科华检验医学产品有限公司 | 一种用于血液采集容器的血液分离胶及其制备方法 |
TWI549756B (zh) * | 2012-02-14 | 2016-09-21 | 國立臺灣大學 | 離心微流碟片及其處理方法 |
CN102690387B (zh) | 2012-05-29 | 2014-07-30 | 南雄阳普医疗科技有限公司 | 用于血清分离胶的树脂、血清分离胶及它们的制备方法 |
CN102764133A (zh) | 2012-08-10 | 2012-11-07 | 上海科华检验医学产品有限公司 | 一种可直接分离血浆的真空采血管及其方法 |
CN102872616B (zh) * | 2012-09-26 | 2014-10-01 | 成都众睿达科技有限公司 | 一种血液分离胶及其制备方法 |
CN104098868A (zh) * | 2013-04-03 | 2014-10-15 | 付士明 | 分离血清或血浆的抗辐照分离胶 |
-
2016
- 2016-06-09 JP JP2017518557A patent/JP6161184B2/ja active Active
- 2016-06-09 US US15/576,689 patent/US10677778B2/en active Active
- 2016-06-09 CN CN201680033584.XA patent/CN107636459B/zh active Active
- 2016-06-09 KR KR1020177024276A patent/KR102424605B1/ko active IP Right Grant
- 2016-06-09 WO PCT/JP2016/067210 patent/WO2016199851A1/ja active Application Filing
- 2016-06-09 EP EP16807557.0A patent/EP3309547B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1010122A (ja) * | 1995-08-28 | 1998-01-16 | Sekisui Chem Co Ltd | 血清又は血漿分離用組成物 |
JP2002365282A (ja) * | 2001-06-05 | 2002-12-18 | Sekisui Chem Co Ltd | 血清または血漿分離用組成物 |
WO2011105151A1 (ja) * | 2010-02-26 | 2011-09-01 | 積水メディカル株式会社 | 血清または血漿分離用組成物及び血液検査用容器 |
JP2013061283A (ja) * | 2011-09-14 | 2013-04-04 | Sekisui Medical Co Ltd | 血清または血漿分離用組成物の滅菌方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3734273A4 (en) * | 2017-12-27 | 2021-09-22 | Sekisui Medical Co., Ltd. | COMPOSITION FOR THE SEPARATION OF BLOOD SERUM OR BLOOD PLASMA, BLOOD COLLECTION CONTAINER AND METHOD FOR SEPARATION OF BLOOD SERUM OR BLOOD PLASMA |
US11719689B2 (en) | 2017-12-27 | 2023-08-08 | Sekisui Medical Co., Ltd. | Composition for separating blood serum or blood plasma, blood collection container, and method for separating blood serum or blood plasma |
WO2020235544A1 (ja) | 2019-05-20 | 2020-11-26 | 積水メディカル株式会社 | 単核球含有血漿分離用組成物及び血液採取容器 |
Also Published As
Publication number | Publication date |
---|---|
US20180136192A1 (en) | 2018-05-17 |
KR20180016721A (ko) | 2018-02-19 |
EP3309547A1 (en) | 2018-04-18 |
JP6161184B2 (ja) | 2017-07-12 |
US10677778B2 (en) | 2020-06-09 |
CN107636459A (zh) | 2018-01-26 |
CN107636459B (zh) | 2020-09-01 |
JPWO2016199851A1 (ja) | 2017-08-10 |
EP3309547A4 (en) | 2019-03-13 |
EP3309547B1 (en) | 2020-10-14 |
KR102424605B1 (ko) | 2022-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6161184B2 (ja) | 血清または血漿分離用組成物、血液検査用容器、並びに血清または血漿分離用組成物の安定化方法 | |
JP5297191B2 (ja) | 血清または血漿分離用組成物及び血液検査用容器 | |
JP5373075B2 (ja) | 血液分離剤及び血液採取容器 | |
EP2410329B1 (en) | Composition for plasma and serum separation, and container for blood testing | |
WO2003048764A1 (fr) | Composition de separation du serum ou du plasma sanguin et contenant renfermant ladite composition, utilises pour l'examen du sang | |
JPH05107245A (ja) | 血液分離剤 | |
CN107209169B (zh) | 血清或血浆分离用组合物、以及血液采取容器 | |
JPWO2007029525A1 (ja) | 血液分離剤用重合体及び血液分離剤組成物 | |
JP3260219B2 (ja) | 血清分離用シーラント | |
JP7513343B2 (ja) | 単核球含有血漿分離用組成物及び血液採取容器 | |
JPH1010122A (ja) | 血清又は血漿分離用組成物 | |
JPH063356A (ja) | 血清又は血漿分離用組成物及び血液検査用容器 | |
JP4504593B2 (ja) | 血清または血漿分離用組成物 | |
JP2013061283A (ja) | 血清または血漿分離用組成物の滅菌方法 | |
BR112014027836B1 (pt) | composição para a produção de material de poliestireno hidrofílico, seu processo de preparação, seu uso e artigo de poliestireno que a compreende | |
JP3303369B2 (ja) | 血液分離剤および血液分離管 | |
JP2002156374A (ja) | 血清または血漿分離用組成物 | |
JPH0249099B2 (ja) | ||
JP2016197132A (ja) | 血清または血漿分離用組成物の滅菌方法 | |
JPH0580044A (ja) | 血液分離剤および血液分離管 | |
JPH07104340B2 (ja) | 血液分離用シ−ラント組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16807557 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017518557 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20177024276 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15576689 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016807557 Country of ref document: EP |